Characteristics of included studies
| Study | Octreotide arm | Control arm | Octreotide dose, route, and frequency | Duration of intervention, d | Quality score | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. of patients | No. of deaths | Pancreatic fistula; no. (and %) | No. of patients | No. of deaths | Pancreatic fistula;no. (and %) | ||||
| Buchler et al (35) | 125 | 4 | 22 (17.6) | 121 | 7 | 46 (38.0) | 100 μg, SC, every 8 h | 7 | 6 |
| Pederzoli et al (43) | 122 | 2 | 11 (9.0) | 130 | 5 | 24 (18.5) | 100 μg, SC, every 8 h | 7 | 6 |
| Friess et al (37) | 122 | 2 | 12 (9.8) | 125 | 1 | 28 (22.4) | 100 μg, SC, every 8 h | 8 | 6 |
| Montorsi et al (42) | 111 | 9 | 10 (9.0) | 107 | 6 | 21 (19.6) | 100 μg, SC, every 8 h | 7 | 6 |
| Lowy et al (41) | 57 | 1 | 16 (28.0) | 53 | 0 | 11 (20.8) | 150 μg, SC, every 8 h | 6 | 6 |
| Yeo et al (45) | 104 | 1 | 11 (10.6) | 107 | 0 | 10 (9.3) | 250 μg, SC, every 8 h | 7 | 5 |
| Gouillat et al (39) | 38 | 2 | 4 (10.5) | 37 | 1 | 10 (27.0) | 600 μg, IV, every 24 h | 6 | 6 |
SC = subcutaneous; IV = intravenous.